City Therapeutics Inc. (NASDAQ: CTY) is a Healthcare company (Biotechnology) with a market capitalization of $170M. The Maz Rating grades it against the other companies in its sector.
City Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $17.50, City Therapeutics Inc. trades at 0.0x sales, with an EV/EBITDA of 1.6. Over the last twelve months it generated about $8.3B of revenue. It runs a gross margin of 70.1%, an operating margin of 35.4% and a net margin of 22.4%. It shows return on equity of 18.3%, return on invested capital of 11.4% and a free cash flow yield of 1331.5%. On the balance sheet: a debt-to-equity ratio of 0.59 and a current ratio of 0.73. Over the past 52 weeks the share price ranged from $15.81 to $23.88, with a beta of 0.00.
City Therapeutics Inc. does not currently pay a dividend.
City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of June 2020, City Therapeutics Inc. (CTY) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2426.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.60% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2426.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.60% / 33% · Receivables / Mkt Cap (36m) 215.0% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2426.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.60% / 33.33% · Receivables / Mkt Cap (24m) 215.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 26.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 0.02% / 33.33% · Receivables / Avg Assets (4Q) 2.35% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 24.0% / 33.33% · (Cash+ST Inv) / Total Assets 0.03% / 33.33% · (Cash+Recv) / Total Assets 2.15% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
It depends on the standard you follow. As of June 2020, City Therapeutics Inc. (CTY) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
No. City Therapeutics Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
City Therapeutics Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated June 30, 2020 (Q2 2020). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.